IMPROVEMENT IN INFLAMMATORY BIOMARKER LEVELS THROUGH WEEK 12 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS PATIENTS TREATED WITH GUSELKUMAB: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
Tadakazu Hisamatsu 1
Laurent Peyrin-Biroulet 2
Axel Dignass 3
Gary KH Huang 4
Matthew Germinaro 4
Nicole Houck 4
Ye Miao 4
Hongyan Zhang 4
Marjorie Costa Argollo 5
Ken Takeuchi 6
Rafal Filip 7
Jessica Allegretti 8
Brian G. Feagan 9
Bruce E. Sands 10
1 Kyorin University, Tokyo, Japan
2 Nancy University Hospital, Université de Lorraine, Nancy, France
3 Agaplesion Markus Hospital, Goethe University, Frankfurt, Germany
4 Janssen Research & Development, LLC, Spring House, United States
5 Onco Star SP Oncologia Ltda, Sao Paulo, Brazil
6 Tsujinaka Hospital Kashiwanoha, Kashiwa, Japan
7 Clinical Hospital No. 2, Rzeszow, Poland
8 Brigham and Women´s Hospital, Boston, United States
9 Alimentiv Inc, London, Canada
10 Icahn School of Medicine at Mount Sinai, New York, United States
Topic
IBD
Session
PP 05 IBD (Posters)
Conference
UEG Week Copenhagen 2023
Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]